Fulgent reached an agreement with two Chinese firms to establish a joint venture to offer genetic testing services in China.
The company will pay nearly $2.1 million to the liquidating trust for the now-bankrupt HDL in order to resolve outstanding debt from a former joint lab venture.
Partnering with Biodist Group, the South Korean molecular diagnostics firm is looking to move into non-human applications such as food safety testing.
Agilent will provide technology and training for the jointly-run lab, expanding on a 2011 deal to open a microarray technology center at Monash University Malaysia.
Emory and Eurofins, following their JV last year, plan to open several clinical genetics labs across the globe that draw on EGL's expertise.
Horizon Discovery will use its experience with gene editing, immunology, and oncology to develop immunotherapies based on Centauri's antibody conjugate technology.
The JV will be based in London with operations in Cambridge, Massachusetts and will develop new treatments for blood disorders, blindness, and congenital heart disease.
DiaGenomi offers a number of tests that combine DNA analysis with information about lifestyle and medical results to provide disease risk assessments.
A private financing fell short of its goal and the IDL joint venture has been unable to its obligations to GeneNews and Cobalt Healthcare, the owners of the JV.
In the second quarter, Quest reported revenues of $1.93 billion and estimated 2015 revenues will be between $7.49 billion and $7.57 billion.
A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.
Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.
Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.
In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.